FDA approves Pfizer's Xeljanz XR

SILVER SPRING, Md. — The Food and Drug Administration on Wednesday approved Pfizer’s Xeljanz XR (tofacitinib citrate) extended-release tablets. 

 

The drug, a once-daily 11-mg dose, is indicated to treat rheumatoid arthritis. It is the first once-daily oral RA treatment in its class of Janus kinase inhibitors, according to Pfizer. 

 

“Pfizer continues to be an innovator in inflammation and immunology,” said Micharl Corbo, Pfizer Global Innovative Pharmaceuticals Business’ category development lead. “The introduction of the first and only once-daily oral JAK inhibitor for RA, XELJANZ XR, builds upon Pfizer’s tradition of developing patient-centered therapies.”